Navigation Links
Gene signature assesses breast cancer outcomes

A test that looks at the expression of 70 genes linked to breast cancer can accurately assess a patient's risk of recurrence or death, according to an article in the September 6 issue of the Journal of the National Cancer Institute.

In previous research, scientists at the Netherlands Cancer Institute in Amsterdam identified 231 genes associated with patient outcomes in a group of patients 55 years or younger with breast tumors under 5 cm. The 231 genes were reduced to a core group of 70 that make up a genetic signature to predict outcomes in a separate group of patients from the same institution.

To determine whether the 70-gene signature performed better than traditional risk classifiers, scientists from the international consortium TRANSBIG assigned 307 patients to high- and low-risk groups based on scores from the 70-gene signature and on traditional risk assessment with the Adjuvant Online! software. The patients were followed for 13.6 years and assessed for disease recurrence and death.

The authors found that the 70-gene signature was a more accurate predictor of disease outcomes than assessment with the Adjuvant Online! software. Moreover, statistical analysis indicated that most of the prognostic information provided by traditional risk classifiers was included in the gene classifier.

The authors write, "These results indicate that the gene signature adds independent prognostic information to that provided by a risk assessment based solely on clinico-pathologic factors."

In an accompanying editorial, Richard Simon, D.Sc., of the National Cancer Institute in Rockville, Md., discusses the strengths and limitations of the study by Buyse et al. He suggests improvements that might have been made in the study's design, and writes that the research, "Illustrate[s] many desirable features of gene expression profiling studies for optimizing treatment selection for individual patients."

The 70-gene signature will be pros pectively tested in a larger study called MINDACT, a trial coordinated by the European Organization for Research and Treatment of Cancer. This trial will assess whether the 70-gene signature can better identify who can safely be spared adjuvant chemotherapy in 6000 women with node-negative early-stage breast cancer. If validated, the tool could safely spare 1 in 6 women the burden of adjuvant chemotherapy.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Bioelectronic ‘signatures?hold key to DNA mutations
2. Eleven gene signature reliably predicts cancer prognosis
3. Common molecular signature identified in solid tumors
4. Novel molecular signature marks DNA of embryonic stem cells
5. Common molecular signature identified in solid tumors
6. Scientists use gene signatures to match cancer and other diseases with potentially effective drugs
7. Molecular signature protects cells from viruses
8. Molecular signature may identify cisplatin-sensitive breast tumors
9. Beyond the DNA: Chemical signatures reveal genetic switches in the genome
10. UCLA study assesses cost-effectiveness of Hepatitis B drugs
11. Viral DNA sequence a possible trigger for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... 12, 2017 , ... MEXICO’S FIRST SPINAL ... announces the successful outcome of the first lumbar fusion procedure in Mexico ... Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to bring ...
(Date:1/12/2017)... , January 12, 2017 The ... world,s biggest facility for producing mycorrhizae. The Centre for ... tapping potential of mycorrhizae and developed a technology that ... ... The TERI facility has a ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical ... promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. ... Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, ...
(Date:1/11/2017)... ... January 11, 2017 , ... With sepsis ... systems more than $23.7 billion, healthcare systems are looking to provide better ... most common sepsis-causing pathogens are bacteria and the yeast pathogen Candida, which can ...
Breaking Biology Technology: